


21st Annual Indy Hematology Review™

Saturday, February 24th 2024 | The Westin Indianapolis

REGISTRATION BROCHURE

Organized by:
Indy Hematology Education, Inc.



Achieving tomorrow's outcomes through education today.™

Presented by:



Plan to participate from 7:30 am – 8:30 pm and earn the full 11 AMA PRA Category 1 Credit(s)™



The Indy Hematology Review™ annually offers a crucial and advanced educational and scientific meeting for hematology professionals. Join others at the Review to examine the current conclusions from leading hematology researchers and educators as they discuss the most recent advances to improve patient management and care. Data from major hematology and oncology conferences of the past year, including the American Society of Hematology, American Society of Clinical Oncology and the European Hematology Association Congress will be reviewed in a fast-paced interactive format, all within a comfortable and collaborative setting.

The Review features broad clinical content, an opportunity to interact with colleagues in a setting with no competing sessions and to discuss out-of-the-box treatments that organically lead to stimulating conversations on specific disease topics throughout the day and during the Town Hall.

Plan to attend the Indy Hematology Review™ to learn critical information and so much more:

- Analyze the new data and research available from respected institutions.
- Assess new therapies available to treat patients and know how to incorporate these therapies into practice.
- Evaluate new drug therapies including the mechanism of action (MOA).
- Identify barriers that may prevent healthcare professionals from implementing new therapies into their practice and understanding steps they can take to address these barriers.
- Modify current practice to improve patient outcomes by incorporating the most current therapies for hematologic malignancies to increase equitable optimal management of treatment plans and care to patients to minimize risk and adverse effects (e.g., toxicity) and improve patient outcomes, survival, and quality of life.

Visit the Exhibit Hall

Visit the exhibit hall to experience the latest developments in hematology treatments. The exhibit hall offers an opportunity to learn about a wide range of products and services offered by pharmaceutical companies, medical suppliers, biotechnology companies, healthcare systems, and research-based companies. Stop in for a beverage and snack as you visit our valued exhibitors.

DISCLOSURE INFORMATION, BIOGRAPHIES, AND SLIDES (WHERE AUTHORIZED BY THE PRESENTER) WILL BE AVAILABLE AT

www.indyhematologyreview.com

QUESTIONS?

Please contact 317-841-7171,
Indyhr@conventionmanagers.com

Register online: www.indyhematologyreview.com

SUPPORTERS & SPONSORSHIPS



Achieving tomorrow's outcomes through education today.™

The 2024 Indy Hematology Review is supported by the following companies as of 12/15/23:

NAME SPONSOR



DIAMOND LEVEL

BeiGene, Ltd
Johnson and Johnson
Innovative Medicine

GOLD LEVEL

Seagen

SILVER LEVEL

Guardant Health

BRONZE LEVEL

Merck

PRODUCT THEATERS

AbbVie
BeiGene, Ltd
Bristol Myers Squibb
Johnson and Johnson
Innovative Medicine
Pfizer Oncology
Seagen

INDY HEMATOLOGY EDUCATION, INC.



Achieving tomorrow's outcomes through education today.™

Indy Hematology Education, Inc. is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

- (a) Raise awareness and provide education regarding hematology and oncology diseases and disorders
- (b) To encourage youth to pursue careers in hematology and oncology and
- (c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs, and service providers.

BOARD OF DIRECTORS

Ruemu E. Birhiray, MD, President and CEO

Michael Wiemann, MD, FACP, Vice-President

Donna M. Birhiray, OT, MBA, Treasurer and COO

Jennifer Terry, JD, Secretary

Thalia Hammond, Director of Conventions

INDY HEMATOLOGY REVIEW PLANNING COMMITTEE

Ruemu Birhiray, MD (Chair)

President and CEO, Indy Hematology Education Inc.
Partner and Vice President,
Hematology Oncology of Indiana, PC

Michael C. Wiemann, MD, FACP (Co-Chair)

VP, Indy Hematology Education Inc.
Regional President and CEO, Ascension Michigan – Metro
West Region
President, Ascension Medical Group, Michigan

Donna Birhiray, OTR, MBA

Indy Hematology Education Inc.
Treasurer and COO

Jennifer Wheeler-Terry, JD

Wabash College, Secretary

Thalia Hammond

Indy Hematology Education Inc.
Director of Conventions

Debbie Locklear, President

Meeting Services Unlimited, Inc.

Tina Machina, CMP, Director of Conventions

Meeting Services Unlimited, Inc.

.....
**“All of the presentation were very
useful and helpful,
and I appreciate the update on
hematology.”**
.....

SYMPOSIUM AGENDA

SATURDAY, FEBRUARY 24, 2024

6:00 AM – 10:00 AM	Registration
6:45 AM – 7:25 AM	Breakfast and Product Theater
6:45 AM – 4:55 PM	Exhibit Hall and Coffee Bar
SESSION CHAIR: Ruemu E. Birhiray, MD	
7:30 AM – 8:00 AM	State of the Art: 2024: Emerging Therapies in Hematologic Malignancies, Ruemu Birhiray, MD
8:00 AM - 8:20 AM	Treatment of Acute Myeloid Leukemias: Managing the AML Patient When Transplant is Not an Option, Harry Erba, MD, PhD
8:20 AM – 8:40 AM	Current, Emerging and Targeted Therapies for the Treatment of Relapsed and Refractory AML, Rami Komrokji, MD
8:40 AM – 9:00 AM	Removing Bad Humor and Targeting Aberrant Signaling: Treatment Strategies of Myelodysplastic Syndromes in 2024, Richard Stone, MD
9:00 AM – 9:20 AM	When the Impossible Becomes Possible: Our Improbable Journey in the Treatment of Acute Lymphoblastic Leukemia, TBA
9:20 AM – 9:30 AM	Myeloid Leukemias PANEL DISCUSSION, Harry Erba, MD, PhD, Rami Komrokji, MD, Richard Stone, MD, TBA
9:30 AM – 9:45 AM	Coffee Break – Exhibit Hall
9:45 AM – 10:10 AM	Emerging and Current Treatment of Multiple Myeloma, Kenneth Anderson, MD
10:10 AM – 10:35 AM	Waldenstrom's Macroglobulinemia: Approaching the Newly Diagnosed and Relapsed Patient, Steven Treon, MD, MA, PhD, FACP, FRCP
10:35 AM – 10:55 AM	Managing Amyloidosis: How We Diagnose and Treat, Morie Gertz, MD, MACP
10:55 AM – 11:05 AM	Plasma Cell Disorders PANEL DISCUSSION, Kenneth Anderson, MD, Steven Treon, MD, MA, PhD, FACP, FRCP, Morie Gertz, MD, MACP
11:05 AM – 11:15 AM	Coffee Break – Exhibit Hall
11:15 AM – 11:40 AM	Controversies in the Management of Chronic Myeloid Leukemia: How I Approach Patients in 2024, Richard Larson, MD
11:40 AM – 12:10 PM	Classical Hematology: Managing Disorders of Bleeding and Clotting and Sickle Cell Disease, Craig Kessler, MD, MACP
12:10 PM – 12:35 PM	Evaluation, Diagnosis and Prognostication and Emerging Therapies for Myeloproliferative Neoplasms, Ayalew Tefferi, MD
12:35 PM – 1:00 PM	Myelofibrosis, Philadelphia Chromosome Negative Myeloproliferative Neoplasms and Systemic Mastocytosis, Raajit Rampal, MD, PhD
1:00 PM – 1:10 PM	Classical and Malignant Hematology PANEL DISCUSSION, Richard Larson, MD, Craig Kessler, MD, MACP, Ayalew Tefferi, MD, Raajit Rampal, MD, PhD, Peter Hillmen, MB, ChB, PhD
1:10 PM – 1:55 PM	Lunch and Product Theaters
1:55 PM – 2:10 PM	Coffee Break – Exhibit Hall
SESSION CHAIR: Michael Wiemann, MD, FACP	
2:10 PM – 2:15 PM	2024 IHE Named Sponsor "Community" Recognition and Presentation of T. Howard Lee Lectureship and Trophy, Michael Wiemann, MD, FACP, Ruemu E. Birhiray, MD, Sumeet Bhatia, MD
2:15 PM – 3:00 PM	T. Howard Lee Keynote Lecture: The Emerging Story of Complementopathies: Treatment of Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia, Robert Brodsky, MD
3:00 PM – 3:05 PM	Questions and Answers
3:05 PM- 3:30 PM	Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do and Know in Community Oncology Practice, Tycel Phillips, MD
3:30 PM – 3:35 PM	Introduction, Presentation and Sponsorship Acknowledgement of Steven Coutre Lecture Medal by the Board of Directors of Indy Hematology Education, Donna Birhiray, OTR, MBA, Jennifer Terry, Thalia Hammond

Register online: www.indyhematologyreview.com

SYMPOSIUM AGENDA

SATURDAY, FEBRUARY 24, 2024

3:35 PM – 4:05 PM	Annual Steven Coutre Chronic Lymphocytic Leukemia Memorial Lecture: Targeted Therapies in Hematologic Disorders Treatment Considerations for Initial Therapy of Chronic Lymphocytic Leukemia, Peter Hillmen, MB, ChB, PhD
4:05 PM – 4:35 PM	Chronic Lymphocytic Leukemia: Evaluating and Therapeutic Approaches for the Management of the Relapsed/Refractory Patient, Jennifer Woyach, MD
4:35 PM – 4:40 PM	Questions and Answers
4:40 PM – 4:55 PM	Coffee Break – Exhibit Hall
4:55 PM – 5:20 PM	When Not to Watch and Wait: Emerging Strategies in the Treatment of Indolent Lymphoma and Mantle Cell Lymphoma, Michael Williams, MD
5:20 PM – 5:45 PM	Current Advances in the treatment of Aggressive B and T Cell Lymphomas, Sonal Smith, MD, FASCO
5:45 PM – 6:10 PM	Emerging and Current Treatment for Hodgkin Lymphoma, Stephen Ansell, MD, PhD
6:10 PM – 6:35 PM	Immune Effector Cell Therapy for Multiple Myeloma: What to Do and Know in Community Oncology Practice, Saad Usmani, MD, MBA, FACP
6:35 PM – 7:00 PM	Hematopoietic Transplantation and Cellular Therapies: When to Refer and Managing Complications, Richard, Childs, MD
7:00 PM – 7:15 PM	Lymphoid Malignancies and Cellular Therapies PANEL DISCUSSION, Ruemu Birhiray, MD, Chair and Moderator Tycel Phillips, MD, Peter Hillmen, MB, ChB, PhD, Jennifer Woyach, MD, Michael Williams, MD Sonali Smith, MD, FASCO, Stephen Ansell, MD, PhD, Saad Usmani, MD, MBA, FACP, Richard Childs, MD
7:15 PM – 7:30 PM	Hors D'oeuvres
7:30 PM – 8:30 PM	Hematologic Malignancies Town Hall Ruemu E. Birhiray, MD – Chair and Moderator Michael Wiemann, MD, FACP – Co-Chair Morie Gertz, MD, MACP – Plasma Cell Disorders and Amyloidosis Jennifer Woyach, MD - Chronic Lymphocytic Leukemia Rami Komrokji, MD - Acute Leukemias and Myelodysplastic Syndromes Tycel Phillips, MD - Lymphomas Saad Usmani, MD, MBA, FACP – Multiple Myeloma Ayalew Teferri, MD – Myeloproliferative Neoplasms

NURSING AND ALLIED PROVIDERS SYMPOSIUM AGENDA

MODERATORS: Donna M. Birhiray, OTR, MBA and Thalia Hammond

6:00 AM – 10:00 AM	Registration
6:45 AM – 7:25 AM	Breakfast and Product Theater
6:45 AM – 4:55 PM	Exhibit Hall and Coffee Bar
7:30 AM – 8:00 AM	State of the Art: 2024: Emerging Therapies in Hematologic Malignancies, Ruemu Birhiray, MD
8:10 AM – 8:35 AM	Emerging and Current Treatment of Waldenstrom's Macroglobulinemia, Steven Treon, MD, MA, PhD, FACP, FRCP
8:35 AM – 9:00 AM	Current Approaches in the Treatment of Myeloproliferative Neoplasms, Ayalew Teferri, MD
9:00 AM – 9:30 AM	Managing Disorders of the Benign Hematology, Craig Kessler, MD, MACP
9:30 AM – 9:45 AM	Coffee Break – Exhibit Hall
9:45 AM – 10:15 AM	Understanding the Diagnosis and Treatment of Plasma Cell Disorders and Amyloidosis, Saad Usmani, MD, MBA, FACP

Register online: www.indyhematologyreview.com

NURSING AND ALLIED PROVIDERS SYMPOSIUM AGENDA

MODERATORS: Donna M. Birhiray, OTR, MBA and Thalia Hammond

10:15 AM – 10:45 AM	Understanding and Managing Immune Effector Toxicities in Hematologic Toxicities, David Reeves, PharmD, BCOP
10:45 AM – 11:15 AM	Management of Long-Term Survivors of Hematologic Malignancies, Sandra Garofalo, MS, APRN, AOCNP
11:15 AM – 11:30 AM	Coffee Break – Exhibit Hall
11:30 AM – 11:55 AM	Recognizing Toxicities of Oral Oncolytics in the Management of Hematologic Malignancies, Kristi Orbaugh, RN, MSN, RNP, AOCN
11:55 AM – 12:25 PM	Current and Emerging Therapies for Acute Myeloid Leukemias and Myelodysplastic Syndromes, Rami Komrokji, MD
12:25 PM – 12:55 PM	How I treat Chronic Myeloid Leukemia: Understanding and Addressing, Richard Larson, MD
12:55 PM – 1:00 PM	Question and Answers
1:10 PM – 1:55 PM	Lunch and Product Theaters
1:55 PM – 2:10 PM	Coffee Break – Exhibit Hall
2:10 PM – 8:30 PM	All join the Main Symposium

REGISTRATION

CLICK HERE TO REGISTER

Early Bird Registration: ends January 19, 2024

Early Bird Physicians	\$245.00
Early Bird Allied Health & Nurses	\$170.00
Early Bird NPs, PAs & Pharmacists	\$195.00
Industry & Exhibitors	\$395.00
Student/Resident/Fellow Scholarship* (Limited Number)	Funded by IHE
Non-Nurse Practitioner Nurses in Clinical Practice Scholarship* (Limited Number)	Funded by IHE
Retired Physicians	\$150.00

Standard Registration: after January 19, 2024

Physicians	\$295.00
Allied Health & Nurses	\$220.00
NPs, PAs & Pharmacists	\$245.00
Industry & Exhibitors	\$395.00
Student/Resident/Fellow Scholarship* (Limited Number)	\$50
Non-Nurse Practitioner Nurses in Clinical Practice Scholarship* (Limited Number)	\$50
Retired Physicians	\$150.00

** **Scholarships:** Indy Hematology Education, Inc. is funding a limited number of scholarships for Fellows, Residents, Medical students, and non-Nurse Practitioner Nurses in clinical practice. (Scholarships are not applicable to NP's, PA's, and Nurses working in the industry). Scholarships are available on a first come, first serve basis until January 19, 2024. A \$25 no show fee will be assessed if you Register but do not attend.*

REFUND POLICY

Request a registration cancellation refund on or before January 19, 2024, to receive a Full Refund (excluding the Processing Fee from Eventbrite). After January 19, 2024, there is NO REFUND.

HOTEL RESERVATIONS

Make reservations **online to reserve a room**. You may also call The Westin Indianapolis toll free at 1-800-937-8461. Reference "Indy Hematology Review" to receive the group rate of \$185 plus tax (currently 17%). The block of discounted rooms will close on February 9, 2024.

PARKING

Parking is available at The Westin Indianapolis. 24-hour parking rates are currently: \$53 on-site parking; \$49 valet. Self-parking is also available at the Government Center Washington St. Parking Facility, 401 West Washington Street: Daily Maximum is \$25. (Rates are subject to change without notice).

PHOTOGRAPHY

Photos of attendees will be taken throughout the Symposium. These photos are for Indy Hematology Review and Indy Hematology Educations, Inc. use only and may appear on the IHR website, in promotional brochures, or other future promotional material. By virtue of your attendance, you agree to usage of your photograph in such media, unless we are otherwise notified in writing and receive a clear photo of you.

"Well formatted educational activity that provides needed updates in one day/location and affords good networking."

Register online: www.indyhematologyreview.com

CONTINUING EDUCATION INFORMATION

The continuing education portion of this activity is being supported by ineligible companies in the form of independent medical education grants. All companies and relationships will be disclosed and mitigated prior to the start of the activity.

PHYSICIANS



In order to receive CE, you must attend the entire Symposium from 7:30 am – 7:15 pm. Successful completion of this CME activity requires participants to complete a post-evaluation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Objectives (ACCME, ANCC, ACPE)

Upon completion of this activity, the participant should be able to:

1. Analyze the new data and research available from respected institutions.
2. Assess new therapies available to treat patients and know how to incorporate these therapies into practice.
3. Evaluate new drug therapies including the mechanism of action (MOA).
4. Identify barriers that may prevent healthcare professionals from implementing new therapies into their practice and understanding steps they can take to address these barriers.
5. Modify current practice to improve patient outcomes by incorporating the most current therapies for hematologic malignancies to increase equitable optimal management of treatment plans and care to patients to minimize risk and adverse effects (e.g., toxicity) and improve patient outcomes, survival, and quality of life.
6. Evaluate the best treatment options for AML patients where transplantation is not an option.
7. Identify the emerging and targeted therapies for the treatment of Relapsed and Refractory AML and describe how to put these treatment options into practice.
8. Identify the emerging treatment options for Myelodysplastic Syndromes and describe how to put these treatment options into practice.
9. Discuss treatment options for managing patients with Chronic Myeloid Leukemia in the current landscape.
10. Identify the new treatment options for Multiple Myeloma and describe how to put these treatment options into practice.
11. Describe management of adverse reactions to Multiple Myeloma therapy.
12. Review the emerging treatment options for Relapsed / Refractory Multiple Myeloma and describe how to put these treatment options into practice.
13. Evaluate the most current and treatment options for Waldenstrom's Macroglobulinemia.
14. Assess and adjust diagnostic and treatment strategies for patients with Amyloidosis to include latest options.
15. Describe the current landscape surrounding treatment recommendations for patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia.
16. Identify the most effective therapies needed to manage bleeding and clotting disorders such as Sickle Cell Disease.
17. Evaluate the diagnosis for Myeloproliferative Neoplasms including how best to treat this disease.
18. Improve the management of patients with Myelofibrosis, Philadelphia Chromosome Negative Myeloproliferative Neoplasms and Systemic Mastocytosis in their practice.
19. Identify the emerging treatment options for Acute Lymphoblastic Leukemia and describe how to put these treatment options into practice.
20. Explain how to effectively implement new Immune Effector Cell therapies for Lymphoid Malignancies in a community practice.
21. Evaluate the diagnosis for cellular blood disorders including how best to treat Initial and Relapsed Chronic Lymphocytic Leukemia.
22. Explain when it is important to "watch and wait" vs. treating patients with Indolent Lymphoma and Mantle Cell Lymphoma.
23. Adjust diagnostic and treatment strategies for patients with Hodgkin's Lymphoma to include latest options.
24. Identify the emerging treatment options for Aggressive B and T Cell Lymphomas and describe how to put these treatment options into practice.
25. Explain how to effectively implement new Immune Effector Cell therapies for Multiple Myeloma in a community practice.
26. Discuss when it is important to refer vs. treat patients who have had Hematopoietic Transplantation and are on Cellular therapies.

Physician Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Purdue University College of Pharmacy designates this live activity for a maximum of *10 AMA PRA Category 1 Credit(s)*[™]. Symposium – 7:30 am – 7:15 pm. Purdue University College of Pharmacy designates this live activity for a maximum of *1.0 AMA PRA Category 1 Credit(s)*[™] (Town Hall Interactive Meeting - 7:30 - 8:30 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosure / Conflict of Interest Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring within the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Disclosures will be provided prior to the start of the activity. All relevant conflicts of interest will have been mitigated prior to the start of the activity.

None of the planners, reviewers, Indy Hematology Education, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

NURSES

In order to receive CE, you must attend the entire Symposium from 7:30 am – 7:15 pm. Successful completion of this CME activity requires participants to complete a post-evaluation.



Nurses Accreditation Statement

Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This program is approved for 9.5 contact hours (Symposium: 7:30 am – 7:15 pm). This program is approved for 1.0 contact hour (Town Hall Interactive Meeting: 7:30 pm - 8:30 pm).

PHARMACISTS

In order to receive CE, you must attend the entire Symposium from 7:30 am – 7:15 pm. Successful completion of this CME activity requires participants to complete a post-evaluation.

Pharmacists Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution.

Symposium: 7:30 am - 7:15 pm.

Universal Activity Number (UAN): 0018-9999-24-001-L01-P
This program is approved for 9.5 contact hours (0.95 CEU's).

Town Hall Interactive Meeting: 7:30 pm - 8:30 pm.

Universal Activity Number (UAN): 0018-9999-24-001-L01-P
This program is approved for 1.0 contact hours (0.10 CEU's).

WEBSITE: <http://www.indyhematologyreview.com/>

Register online: www.indyhematologyreview.com



Indy Hematology Review
135 S. Mitthoeffer Rd.
Indianapolis, IN 46229

21st Annual Indy Hematology Review™

Saturday, February 24th 2024 | The Westin Indianapolis

Organized by:
Indy Hematology Education, Inc.



Achieving tomorrow's outcomes through education today.™

Presented by:

